HIV drug resistance has tremendous consequences in terms of treatment failure and overall health care costs. Sanger sequencing‐based assays have been the preferred genotyping method, however, it has been recognized that they are limited in their ability todetect critical minority variants below 20% frequency.
Detecting rare HIV variants is critical
As more and more clinical laboratories employ NGS technologies to detect rare variants as low as 1%, robust HIV drug resistance reference materials are critical to ensure the accurate detection of drug resistance mutations which ultimately affect treatment outcomes.
As a key component in NGS quality control practices, Seraseq™ HIV-1 Reference Materials provide a consistent, multiplexed and reliable source of NGS-characterized reference material to assess performance across the entire workflow for NGS and Sanger-based assays that screen for HIV-1 drug resistance mutations. Seraseq™ HIV-1 Drug Resistance and Tropism Reference Material can help you assess low frequency variants and easily determine the limit of detection. Created with AccuPlex™ recombinant viral technology, this reference material evaluate the detection of 49 clinically actionable mutations across protease (PRO), reverse transcriptase (RT), and integrase (INT) regions in a single product. The reference material also contains envelope sequences indicative of either CCR5 or CXCR4 co-receptor usage (tropism).
AccuPlex recombinant technology
AccuPlex-based NGS reference materials are constructed with a replication-deficient mammalian virus (RNA or DNA) containing a known target sequence (such as the HIV-1 drug resistance mutations). With a protein coat and lipid bilayer, these mammalian virus-based reference materials resemble the complexity of virus targets found in patient samples, and can be used as a full process reference material to evaluate the sequencing workflow from extraction through data analysis.